We are proud to introduce Oslo Cancer Cluster’s new members. This is the first part of two stories about our new members.
You can find the second part HERE.
On the 24th of August, Oslo Cancer Cluster hosted a summer party with the intention of getting to know their newest members in an informative and fun setting. The party started with a heartfelt welcome and speech held by Oslo Cancer Cluster’s General Manager Ketil Widerberg and intensive mingling amongst guests. After the welcome was in order, each member stood up, in turn, to introduce their amazing work.
Of the 14 new members we have so far this year, here’s an introduction to those who primarily work in the area of biotechnology.
Precision Oncology is a specialty contract research organization (CRO) that provides clinical research services. The company primarily provides application of metrics-driven project management to perfect oncology drug development.
As for their inspiration and reasoning for joining the Oslo Cancer Cluster roster of members, Andrea Cotton-Berry, head of Strategic operations at Precision Oncology, responds:
– What really inspires us at Precision Oncology, is matching the right drug to the right patient, by using biomarkers for patient identification and stratification; a true personalized medicine approach, to find more efficient treatments for patients with advanced cancers. We are looking forward to bringing our team of oncology development experts to contribute to the Oslo Cancer Cluster mission and initiatives, especially advancing immuno-oncology research.
Personalis is a leading preciscion medicine company focused on advancing next generation sequencing based services for immuno-oncology. The company is mainly focused on producing the most accurate genetic sequence from each sample set, and using analytics and privately owned content to draw reliable and accurate biomedical interpretations of the data.
In regards to current and future inspiration, Erin Newburn, Senior Manager and Field Applications Scientist at Personalis, comments:
– We aspire to utilize next-generation sequencing as a multi-dimensional platform for bio-marker discovery across cancer therapeutics, as well as throughout developmental stages.
iNANOD is a nanotechnology based anti-cancer drug developing company established in 2016. Their goal is to increase efficacy of anti-cancer drugs and to reduce side-effects for cancer patients as well as maximizing the patients longevity. They aim to become a pharmaceutical company for anti-cancer nanomedicines in the near future.
As for expectations and reasoning for joining Oslo Cancer Cluster, Nalinava Sengupta, CEO and Co-Founder of iNANOD shares his view:
– We think our project – to develop cancer nano-medicine – fits best with Oslo Cancer Cluster. In the incubator we get in touch with other similar firms who have achieved milestones in cancer drug delivery. We expect synergistic knowledge transfer within the incubator network, as well as various kinds of help from the cancer research related entrepreneurial ecosystem developed at Oslo Cancer Cluster. This also helps with business developmental aspects and project application writing.
Norgenotech is a start-up company that originated from the EU project COMICS that aimed at improving production methods for analysis of DNA damage and repair. Norgenotech mainly assesses genotoxicity, or property of chemical agents that damage the genetic information within a cell, as well as drugs. The company also participates in research projects and developing tools for measuring DNA integrity in patients.
Eisai AB originates from a global company in Japan that is active in the manufacturing and marketing of pharmaceutical drugs, pharmaceutical production systems, and over-the-counter drugs. Eisai AB, that will be joining the Oslo Cancer Cluster roster of members, is the sales subsidiary of Eisai Company.
Immunitrack is a startup company with capabilities in production and studies of protein molecules central to the adaptive immune system in humans in order to develop new therapeutics. Their mission is to provide the research community with tools to redesign or select drug candidates at the early stage of research and development, but also to provide reagents to monitor leading drug candidates effect on patient’s immune system.
Nacamed’s goal is to produce nanoparticles of silicon material for targeted drug delivery of chemotherapy, radiation therapy and diagnostics to kill cancer cells. By using silicon nanoparticles in cases such as therapy, the particles are biodegradable which entails a clean delivery without any side-effects as they completely disappear and dissolve from the body.
Arctic Pharma is a privately held startup biotech company founded in 2012 that primarily focuses on developing innovative anti-cancer drugs. They do this by exploiting cancer cells and their peculiar features, or more specifically, by targeting key enzymes that are upregulated, or have been increased in terms of stimulus with inhibitors designed at Arctic Pharma. Essentially, their main mission is to become a leader in designing cancer therapies that are both environmentally friendly and have few side effects.